2026 Q1 -tulosraportti
Vain PDF
14 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 90 | - | - | ||
| 5 | - | - | ||
| 5 | - | - | ||
| 6 990 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 13.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·9 t sittenIt's absolutely insane that the company has spent 1.5 weeks clarifying ambiguities. As soon as it's possible, I will flee this company for such a mess.
·9 t sittenThe sell button is available today. The opportunity is there 👌·9 t sittenHoping for a bounce a few percent. It can happen! The company is down 50% this year and almost doesn't give a damn about the market
·1 päivä sittenClosed trading around 2 PM today?·16 t sittenNo. But it was completely dry on the buyer and seller side.
·22.5.Good with insider buying, even if the volume wasn't all that much. So let's hope the rest of the board also buys. The options the board members were allocated cannot be exercised at a price lower than kr. 4,- so they should top up with some shares.
·20.5.This one has taken a big hit. Is it a buying opportunity now that the price development seems to have turned around?·21.5.The company promised to release a qna within a few days. It's a week since they said that. I'm struggling a bit with the trust, I feel... 😅- ·15.5.Chat GPT: Part 2 3. The NHS/RTP track is important This is very interesting: They are now trying to get funding indirectly via the NHS program: “Respiratory Transformation Pathway”. This means: * NHS can potentially finance the rollout, * which reduces sales friction, * and can make scaling much faster. The 10 million GBP program is explicitly mentioned. This seems like an attempt to get: * publicly funded national rollout, * instead of traditional heavy enterprise sales. It can be strategically smart. 4. They are building an AI angle The company mentions: * AI-driven features, * automation, * master data, * clinical decision support. This is important because: the market gives higher value to software companies that can connect: * health data, * workflow, * and AI. But for now, this seems more like positioning than large commercial revenues. 5. The grant portal is both a strength and a weakness This is still a stable foundation: * ~40 % market share in Norway, * recurring subscription revenues, * public sector customers. But: municipalities are cutting costs. They say directly that: * customer churn increased, * municipalities are cutting "non-obligatory" services. This is a real risk. At the same time, they show that: voluntary organizations found over 60 MNOK in support via the solution. That strengthens the product's value proposition. 6. Sweden seems weaker than the market perhaps hoped They write quite clearly between the lines: * the market is more difficult, * more fragmented, * and go-to-market must be evaluated. It is not negatively catastrophic, but also not a sign of rapid scaling. 7. Intangible assets are high They have: * 50,2 MNOK in intangible assets, * against 16,7 MNOK in revenue. This is high. Consists of: * developed platforms, * goodwill from the OSINT acquisition. Risk: If growth fails to materialize, the market may start to question these values. My assessment of the message Fundamentally: This is clearly better than previous annual reports. It looks like: * financial cleanup work has actually worked, * and that the company now has a bit more breathing room. What the market probably focuses most on Positive 1. EBITDA significantly improved 2. Debt dramatically reduced 3. Positive cash flow 4. AstraZeneca/NHS dialogue continues 5. 60–70 MNOK ARR potential explicitly mentioned Negative 1. No signed UK agreement yet 2. Falling revenues 3. Customer churn in the municipal market 4. Still a loss on the bottom line Overall investment case now Induct now seems more like: * a restructured software/healthtech case, than a company in acute financial distress. The future value is probably almost entirely determined by: * whether the UK/AstraZeneca/NHS track materializes, * and whether they manage to convert pilot/project to scalable ARR. If they succeed: today's size can be very small relative to the potential. If they fail: they are left with: * a moderate Norwegian software business, * weak growth, * and limited scaling.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
14 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenIt's absolutely insane that the company has spent 1.5 weeks clarifying ambiguities. As soon as it's possible, I will flee this company for such a mess.·9 t sittenThe sell button is available today. The opportunity is there 👌·9 t sittenHoping for a bounce a few percent. It can happen! The company is down 50% this year and almost doesn't give a damn about the market
- ·1 päivä sittenClosed trading around 2 PM today?·16 t sittenNo. But it was completely dry on the buyer and seller side.
- ·22.5.Good with insider buying, even if the volume wasn't all that much. So let's hope the rest of the board also buys. The options the board members were allocated cannot be exercised at a price lower than kr. 4,- so they should top up with some shares.
- ·20.5.This one has taken a big hit. Is it a buying opportunity now that the price development seems to have turned around?·21.5.The company promised to release a qna within a few days. It's a week since they said that. I'm struggling a bit with the trust, I feel... 😅
- ·15.5.Chat GPT: Part 2 3. The NHS/RTP track is important This is very interesting: They are now trying to get funding indirectly via the NHS program: “Respiratory Transformation Pathway”. This means: * NHS can potentially finance the rollout, * which reduces sales friction, * and can make scaling much faster. The 10 million GBP program is explicitly mentioned. This seems like an attempt to get: * publicly funded national rollout, * instead of traditional heavy enterprise sales. It can be strategically smart. 4. They are building an AI angle The company mentions: * AI-driven features, * automation, * master data, * clinical decision support. This is important because: the market gives higher value to software companies that can connect: * health data, * workflow, * and AI. But for now, this seems more like positioning than large commercial revenues. 5. The grant portal is both a strength and a weakness This is still a stable foundation: * ~40 % market share in Norway, * recurring subscription revenues, * public sector customers. But: municipalities are cutting costs. They say directly that: * customer churn increased, * municipalities are cutting "non-obligatory" services. This is a real risk. At the same time, they show that: voluntary organizations found over 60 MNOK in support via the solution. That strengthens the product's value proposition. 6. Sweden seems weaker than the market perhaps hoped They write quite clearly between the lines: * the market is more difficult, * more fragmented, * and go-to-market must be evaluated. It is not negatively catastrophic, but also not a sign of rapid scaling. 7. Intangible assets are high They have: * 50,2 MNOK in intangible assets, * against 16,7 MNOK in revenue. This is high. Consists of: * developed platforms, * goodwill from the OSINT acquisition. Risk: If growth fails to materialize, the market may start to question these values. My assessment of the message Fundamentally: This is clearly better than previous annual reports. It looks like: * financial cleanup work has actually worked, * and that the company now has a bit more breathing room. What the market probably focuses most on Positive 1. EBITDA significantly improved 2. Debt dramatically reduced 3. Positive cash flow 4. AstraZeneca/NHS dialogue continues 5. 60–70 MNOK ARR potential explicitly mentioned Negative 1. No signed UK agreement yet 2. Falling revenues 3. Customer churn in the municipal market 4. Still a loss on the bottom line Overall investment case now Induct now seems more like: * a restructured software/healthtech case, than a company in acute financial distress. The future value is probably almost entirely determined by: * whether the UK/AstraZeneca/NHS track materializes, * and whether they manage to convert pilot/project to scalable ARR. If they succeed: today's size can be very small relative to the potential. If they fail: they are left with: * a moderate Norwegian software business, * weak growth, * and limited scaling.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 90 | - | - | ||
| 5 | - | - | ||
| 5 | - | - | ||
| 6 990 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 13.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
14 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 13.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·9 t sittenIt's absolutely insane that the company has spent 1.5 weeks clarifying ambiguities. As soon as it's possible, I will flee this company for such a mess.·9 t sittenThe sell button is available today. The opportunity is there 👌·9 t sittenHoping for a bounce a few percent. It can happen! The company is down 50% this year and almost doesn't give a damn about the market
- ·1 päivä sittenClosed trading around 2 PM today?·16 t sittenNo. But it was completely dry on the buyer and seller side.
- ·22.5.Good with insider buying, even if the volume wasn't all that much. So let's hope the rest of the board also buys. The options the board members were allocated cannot be exercised at a price lower than kr. 4,- so they should top up with some shares.
- ·20.5.This one has taken a big hit. Is it a buying opportunity now that the price development seems to have turned around?·21.5.The company promised to release a qna within a few days. It's a week since they said that. I'm struggling a bit with the trust, I feel... 😅
- ·15.5.Chat GPT: Part 2 3. The NHS/RTP track is important This is very interesting: They are now trying to get funding indirectly via the NHS program: “Respiratory Transformation Pathway”. This means: * NHS can potentially finance the rollout, * which reduces sales friction, * and can make scaling much faster. The 10 million GBP program is explicitly mentioned. This seems like an attempt to get: * publicly funded national rollout, * instead of traditional heavy enterprise sales. It can be strategically smart. 4. They are building an AI angle The company mentions: * AI-driven features, * automation, * master data, * clinical decision support. This is important because: the market gives higher value to software companies that can connect: * health data, * workflow, * and AI. But for now, this seems more like positioning than large commercial revenues. 5. The grant portal is both a strength and a weakness This is still a stable foundation: * ~40 % market share in Norway, * recurring subscription revenues, * public sector customers. But: municipalities are cutting costs. They say directly that: * customer churn increased, * municipalities are cutting "non-obligatory" services. This is a real risk. At the same time, they show that: voluntary organizations found over 60 MNOK in support via the solution. That strengthens the product's value proposition. 6. Sweden seems weaker than the market perhaps hoped They write quite clearly between the lines: * the market is more difficult, * more fragmented, * and go-to-market must be evaluated. It is not negatively catastrophic, but also not a sign of rapid scaling. 7. Intangible assets are high They have: * 50,2 MNOK in intangible assets, * against 16,7 MNOK in revenue. This is high. Consists of: * developed platforms, * goodwill from the OSINT acquisition. Risk: If growth fails to materialize, the market may start to question these values. My assessment of the message Fundamentally: This is clearly better than previous annual reports. It looks like: * financial cleanup work has actually worked, * and that the company now has a bit more breathing room. What the market probably focuses most on Positive 1. EBITDA significantly improved 2. Debt dramatically reduced 3. Positive cash flow 4. AstraZeneca/NHS dialogue continues 5. 60–70 MNOK ARR potential explicitly mentioned Negative 1. No signed UK agreement yet 2. Falling revenues 3. Customer churn in the municipal market 4. Still a loss on the bottom line Overall investment case now Induct now seems more like: * a restructured software/healthtech case, than a company in acute financial distress. The future value is probably almost entirely determined by: * whether the UK/AstraZeneca/NHS track materializes, * and whether they manage to convert pilot/project to scalable ARR. If they succeed: today's size can be very small relative to the potential. If they fail: they are left with: * a moderate Norwegian software business, * weak growth, * and limited scaling.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 90 | - | - | ||
| 5 | - | - | ||
| 5 | - | - | ||
| 6 990 | - | - | ||
| 9 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt